Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01773837 : Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
PhasePhase 3
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Advanced cancer; including metastatic, locally advanced or relapsed not amenable for
curative treatment.

- Mini.mental status examination results within normal limits.

- Informed consent.

- Estimated life expectancy of at least one month.

- Hemoglobin >= 9 g/dl.

- Asthenia >= 5 (0-10; numeric verbal scale).

Exclusion Criteria:

- History of psychosis.

- Structured suicidal ideation.

- Severe anxiety.

- Severe renal, hepatic or cardiac (arrythmia, hypertension, ischemic heart disease)

- Simultaneous treatment with drugs that may interact with methylphenidate as:
coumarinics, anticonvulsivants (phenobarbital, phenitoin, primidone), phenylbutazone,
inhibitors of mono-amine-oxidase, guanethidine.

- History of glaucoma.

- Hyperthyroidism.

- History of hypersensibility to methylphenidate.

- Clinical suspicion of: infection, hypercalcemia, hypothyroidism or renal failure.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557